Drugs / YPEG rhEPO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04885647 | Mar 2021 → Jan 2022 | anemia due to chronic disorder | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YPEG rhEPO | “YPEG rhEPO, a recombinant human erythropoietin pegylated by Y shape polyethylene glycol” NCT04885647 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant human erythropoietin pegylated by Y shape polyethylene glycol” NCT04885647 ↗ |
| Route | Subcutaneous | “were subcutaneous injected once every two weeks for 13 weeks.” NCT04885647 ↗ |